---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-058864"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2026-08-25T20:06:36+00:00"
generated_at: "2026-08-25T20:08:28.935835+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma gets FDA approval for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma

## Summary
- FDA approved Ziihera (zanidatamab-hrii) plus Tevimbra (tislelizumab-jsgr) and chemo for all HER2+ GEA (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status.
- Second approval: Ziihera plus chemo for HER2+ IHC 3+ GEA; based on Phase 3 HERIZON-GEA-01 trial.
- Trial showed 35% PFS risk reduction (12.4 vs 8.1 months) and 28% OS risk reduction (26.4 vs 19.2 months) vs trastuzumab plus chemo.
- Jazz hosts investor webcast Aug 25, 4:30pm ET; Ziihera is first bispecific HER2-targeted antibody plus PD-1 inhibitor approved in this setting.

## SEC filing metadata
- accession: 0001628280-26-058864
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2026-08-25T20:06:36+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/0001628280-26-058864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/jazz-20260825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-058864
- JSON: https://secwatch.observer/filing/0001628280-26-058864.json
- Plain text: https://secwatch.observer/filing/0001628280-26-058864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.